31 results on '"Nault A"'
Search Results
2. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response
3. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
4. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation
5. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
6. A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
7. Hepatocellular Benign Tumors—From Molecular Classification to Personalized Clinical Care
8. Intermediate Hepatobiliary Cells Predict an Increased Risk of Hepatocarcinogenesis in Patients With Hepatitis C Virus-Related Cirrhosis
9. Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?
10. A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma
11. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator
12. A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma
13. Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?
14. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator
15. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation
16. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
17. Genotype-phenotype relationships in hepatocellular carcinoma: p53 inactivation promotes tumors with stem cell features
18. Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis
19. Genotype–Phenotype Relationships in Hepatocellular Carcinoma: p53 Inactivation Promotes Tumors With Stem Cell Features
20. Tegaserod provides rapid and sustained relief of constipation, abdominal bloating/distension, and abdominal discomfort/pain in patients with chronic constipation
21. Safety and tolerability of tegaserod in patients treated for chronic constipation (CC): A 12-week, double-blind, placebo-controlled multicenter study performed in the americas
22. Tegaserod provides rapid and sustained relief of constipation, abdominal bloating/distension, and abdominal discomfort/pain in patients with chronic constipation
23. Early effect of tegaserod predicts continued efficacy in treatment of constipation predominant irritable bowel syndrome
24. Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)
25. Safety and tolerability of tegaserod in patients treated for chronic constipation (CC): A 12-week, double-blind, placebo-controlled multicenter study performed in the americas
26. Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
27. Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)
28. Early effect of tegaserod predicts continued efficacy in treatment of constipation predominant irritable bowel syndrome
29. Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
30. Tegaserod, a 5-HT 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
31. Tegaserod, a 5-HT4receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.